Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2. > 연구자료실

본문 바로가기

연구자료실

연구자료실
IP: ***.***.***.4.1

Small heterodimer partner-targeting therapy inhibits systemic inflamma…

페이지 정보

최고관리자 조회수 : 1,018

본문

PLoS One. 2013 May 21;8(5):e63435. doi: 10.1371/journal.pone.0063435. Print 2013.

Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2.

Abstract

The orphan nuclear receptor, small heterodimer partner (SHP), appears to play a negative regulatory role in innate immune signaling. Emerging evidence warrants further study on the therapeutic targeting of SHP to suppress excessive and deleterious inflammation. Here we show that fenofibrate, which targets SHP, is required for inhibiting systemic inflammation via mitochondrial uncoupling protein 2 (UCP2). In vivo administration of fenofibrate ameliorated systemic inflammatory responses and increased survival upon experimental sepsis through SHP. An abundance of SHP was observed in mice fed fenofibrate and in cultured macrophages through LKB1-dependent activation of the AMP-activated protein kinase pathway. Fenofibrate significantly blocked endotoxin-triggered inflammatory signaling responses via SHP, but not via peroxisome proliferator-activated receptor (PPAR)-α. In addition to the known mechanism by which SHP modulates innate signaling, we identify a new role of fenofibrate-induced SHP on UCP2 induction, which is required for the suppression of inflammatory responses through modulation of mitochondrial ROS production. These data strongly suggest that the SHP-inducing drug fenofibrate paves the way for novel therapies for systemic inflammation by targeting SHP.

대표 : 김좌진 ㅣ 개인정보관리 : 김좌진 ㅣ 사업자번호 : 253-86-01081 ㅣ 통신판매업신고: 2018-대전동구-0190호
본사 : 대전광역시 동구 충정로 21, 4105호 ㅣ 기업부설연구소 : 대전광역시 동구 충정로 21, 4104호
당사는 모든 이미지의 무단사용을 금하며, 무단사용시 저작권법 98조에 의거 민형사상 책임을 지게됩니다.
COPYRIGHT ©2019 (주)프로셀컴퍼니. ALL RIGHTS RESERVED.